Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback